ALLO Allogene Therapeutics, Inc.
Price Chart
Executive Summary
Allogene Therapeutics announced a CEO transition: David Chang, M.D., Ph.D., will step down as President and CEO effective June 30, 2026, and will be succeeded by current EVP of R&D and CMO Zachary Roberts, M.D., Ph.D., effective July 1, 2026. Dr. Chang will remain on the board as a non-employee director. Dr. Roberts received a new compensation package including $680,000 base salary, options for 476,190 shares, and 134,530 RSUs.
Actionable Insight
CEO transition with an insider promotion suggests continuity in strategy — no material change in operations or pipeline. The outgoing founder CEO staying on the board reduces disruption risk. Monitor the July effective date for any strategic shifts; the prior proxy fight context adds modest governance uncertainty. No immediate trading catalyst.
Key Facts
- CEO David Chang departing June 30, 2026; Dr. Chang remains on board as non-employee director
- Zachary Roberts appointed President and CEO effective July 1, 2026; also appointed Class I director
- Dr. Roberts previously served as EVP R&D and CMO since Jan/Apr 2023
- New CEO base salary: $680,000; target cash incentive: 60% of salary
- Equity grants: option for 476,190 shares (4yr vest, 1yr cliff), RSU for 134,530 shares (4yr annual vest)
- Dr. Chang eligible for severance under Company's Change in Control and Severance Benefit Plan
- Cross-filing: DEFA14A filed 4/30/2026 — proxy fight materials contested election context
Financial Impact
Compensation package for new CEO includes $680K salary and equity grants covering ~611K shares total (option + RSU)
Risk Factors
- Founder CEO departure at a clinical-stage biotech may signal strategic or pipeline concerns
- Recent proxy contest context (DEFA14A 4/30) adds governance uncertainty
- Equity grants could cause modest future dilution (~0.4% on ~610K shares vs ~777M market cap)
Market Snapshot
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-245484 |
| Document: 0001193125-26-245484-index-headers.html | 0001193125-26-245484 |
| Document: 0001193125-26-245484-index.html | 0001193125-26-245484 |
| Document: 0001193125-26-245484.txt | 0001193125-26-245484 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 28, 2026
12d ago
|
DEFA14A
| $2.17 $1.88 | ▼ −13.36% | ▼ −10.84% | $1.85 (−14.75%) |
|
May 28, 2026
12d ago
|
8-K
| $2.17 $1.88 | ▼ −13.36% | ▼ −10.84% | $1.85 (−14.75%) |
|
May 28, 2026
12d ago
|
Press Release
| $2.17 $2.00 | ▼ −7.83% | ▼ −7.54% | $1.85 (−14.75%) |
|
Apr 21, 2026
7w ago
|
Press Release
| $2.32 $2.19 | ▼ −5.60% | ▼ −6.69% | $1.85 (−20.26%) |
|
Apr 15, 2026
7w ago
|
8-K
| $2.37 $2.35 | ▼ −0.84% | ▼ −1.83% | $1.85 (−21.94%) |
|
Apr 15, 2026
7w ago
|
424B5
| $2.37 $2.35 | ▲ +0.84% | ▲ +1.83% | $1.85 (+21.94%) |
|
Apr 15, 2026
7w ago
|
Press Release
| $2.17 $2.39 | ▲ +10.14% | ▲ +8.50% | $1.85 (−14.75%) |
|
Apr 15, 2026
8w ago
|
Press Release
| $2.17 $2.39 | ▼ −10.14% | ▼ −8.50% | $1.85 (+14.75%) |
|
Apr 13, 2026
8w ago
|
424B5
| $2.28 $2.32 | ▲ +1.75% | ▲ +0.36% | $1.85 (−18.86%) |
|
Apr 13, 2026
8w ago
|
8-K
| $2.28 $2.32 | ▼ −1.75% | ▼ −0.36% | $1.85 (+18.86%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access